Performance of commercial platforms for rapid genotyping of polymorphisms affecting warfarin dose

American Journal of Clinical Pathology

Volumn 129, Issue 6, 2008, Pages 876-883

  King, Cristi R ^a   Porche Sorbet, Rhonda M ^a   Gage, Brian F ^a   Ridker, Paul M ^b   Renaud, Yannick ^c   Phillips, Micheal S ^c   Eby, Charles ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c MONTREAL HEART INSTITUTE   (Canada)

Author keywords

CYP2C9; Genotyping; Pharmacogenetics; VKORC1; Warfarin

Indexed keywords

CYTOCHROME P450 2C9; MENADIONE EPOXIDE; VITAMIN K EPOXIDE REDUCTASE COMPLEX 1; WARFARIN; ANTICOAGULANT AGENT; CYP2C9 PROTEIN, HUMAN; MENADIONE EPOXIDASE; MIXED FUNCTION OXIDASE; UNSPECIFIC MONOOXYGENASE;

ACCURACY; ANALYZER; ARTICLE; DNA DETERMINATION; DNA SEQUENCE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PYROSEQUENCING; SINGLE NUCLEOTIDE POLYMORPHISM; COMPARATIVE STUDY; DOSE RESPONSE; EVALUATION; GENETICS; METHODOLOGY; NUCLEOTIDE SEQUENCE; REPRODUCIBILITY;

ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; DNA MUTATIONAL ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; GENOTYPE; HUMANS; MIXED FUNCTION OXYGENASES; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; REPRODUCIBILITY OF RESULTS; SEQUENCE ANALYSIS, DNA; WARFARIN;

EID: 42549147383     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/1E34UAPR06PJ6HML     Document Type: Article

References (28)

1. Ansell J, Hirsh J, Poller L, et al. The pharmacology and management of vitamin K antagonists: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest. 2004;126(suppl):204S-233S.
2. Linkins L, Choi P, Douketis J. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta analysis. Ann Intern Med. 2003;139:893-900.
3. Higashi MK, Veenstra DL, Kondo LM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA. 2002;287:1690-1698.
4. Gage BF, Eby CS. The genetics of vitamin K antagonists. Pharmacogenomics J. 2004;4:224-225.
5. Sconce EA, Khan TI, Wynne HA, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood. 2005;106:2329-2333.
6. Wadelius M, Chen LY, Downes K, et al. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J. 2005;5:262-270.
7. Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med. 2005;352:2285-2293.
8. Furuya H, Gernandez-Salguero P, Gregory W, et al. Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirements in patients undergoing anticoagulation therapy. Pharmacogenetics. 1995;5:389-392.
9. Yuan H, Chen J, Lee M, et al. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum Mol Genet. 2005;14:1745-1751.
10. Millican EA, Lenzini PA, Milligan PE, et al. Genetic-based dosing in orthopedic patients beginning warfarin therapy. Blood. 2007;110:1511-1515.
11. Wood S. New warfarin labeling reminds physicians about genetic tests to help guide initial warfarin dosing. Medscape. Available at http://www.medscape.com/viewarticle/561608. Accessed September 4, 2007.
12. Ridker PM, Goldhaber SZ, Danielson E, et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med. 2003;348:1425-1434.
13. Gage B, Eby C, Johnson J, et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther. February 27, 2008. epub ahead of print.
14. Vairavan R. AutoGenomics, Inc. Pharmacogenomics. 2004;5:585-588.
15. de Arruda M, Lyamichev VI, Eis PS, et al. Invader technology for DNA and RNA analysis: principles and applications. Expert Rev Mol Diagn. 2002;2:487-496.
16. Lyamichev V, Mast AL, Hall JG, et al. Polymorphism identification and quantitative detection of genomic DNA by invasive cleavage of oligonucleotide probes. Nat Biotechnol. 1999;17:292-296.
17. Strom CM, Janeczko RA, Anderson B, et al. Technical validation of a multiplex platform to detect thirty mutations in eight genetic diseases prevalent in individuals of Ashkenazi Jewish descent. Genet Med. 2005;7:633-639.
18. Ronaghi M. Pyrosequencing sheds light on DNA sequencing. Genome Res. 2001;11:3-11.
19. King CR, Scott-Horton T. Pyrosequencing: a simple method for accurate genotyping. Methods Mol Biol. 2006;373:39-56.
20. Ronaghi M, Uhlén M, Nyrén P. A sequencing method based on real-time pyrophosphate. Science. 1998;281:363, 365.
21. Gage BF. Pharmacogenetics-based coumarin therapy. Hematology Am Soc Hematol Educ Program. 2006:467-473.
22. Voora D, Eby C, Linder MW, et al. Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype. Thromb Haemost. 2005;93:700-705.
23. Hillman MA, Wilke RA, Yale SH, et al. A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data. Clin Med Res. 2005;3:137-145.
24. Kidd RS, Curry TB, Gallagher S, et al. Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. Pharmacogenetics. 2001;11:803-808.
25. Allabi AC, Gala JL, Horsmans Y, et al. Functional impact of CYP2C95, CYP2C96, CYP2C98, and CYP2C911 in vivo among black Africans. Clin Pharmacol Ther. 2004;76:113-118.
26. Rettie AE, Farin FM, Beri NG, et al. A case study of acenocoumarol sensitivity and genotype-phenotype discordancy explained by combinations of polymorphisms in VKORC1 and CYP2C9. Br J Clin Pharmacol. 2006;62:617-620.
27. Rettie AE, Tai G, Veenstra DL, et al. CYP2C9 exon 4 mutations and warfarin dose phenotype in Asians [letter]. Blood. 2003;101:2896-2897.
28. Loebstein R, Dvoskin I, Halkin H, et al. A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance. Blood. 2006;109:2477-2480.